Archive: June 2023

New Drug Approvals in Prostate Cancer and Their Effect on the Treatment Landscape

Abstract: Prostate cancer is the most frequently diagnosed non-skin cancer and the second leading cause of cancer-related mortality in men in the United States. Over the […]

Evolving Landscape of Targeted Treatment Options for HER2-Positive Gastric/Gastroesophageal Adenocarcinomas

Abstract: Gastric and gastroesophageal adenocarcinomas are aggressive malignancies despite current standard-of-care treatments. For patients whose tumors express human epidermal growth factor receptor 2 (HER2), HER2-targeted treatments […]

Is Blinatumomab Now Standard of Care Consolidation for Patients With ALL?

H&O  What is blinatumomab and how does it work in treating acute lymphocytic leukemia (ALL)? SL  Blinatumomab (Blincyto, Amgen), which is classified as a bispecific antibody, […]

Advances in SERDs and Other Novel Endocrine Therapies

H&O  What are the main challenges with endocrine therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer?  KK  The first […]

Update on the DREAMseq Trial in Melanoma

H&O  What was the impetus for the DREAMseq trial? MA  In 2015, there were 2 different approaches to treating patients with metastatic BRAF-mutant melanoma, both of […]

Letter From the Editor: I Wish I Knew . . .

On April 6, 2023, AbbVie announced its intent to voluntarily withdraw its accelerated approval for ibrutinib in mantle cell lymphoma and marginal zone lymphoma in the […]

Managing CLL That Has Progressed After BTK Inhibition

H&O  When patients with chronic lymphocytic leukemia (CLL) progress while on Bruton tyrosine kinase (BTK) inhibitor therapy, what is your next therapy of choice? LR  Because […]

Predictive Biomarkers in Advanced Prostate Cancer

H&O  What is the difference between a prognostic biomarker and a predictive biomarker? AA  Prognostic biomarkers estimate the natural history of a disease, or in other […]

Back to Archive